Opinion|Videos|April 4, 2025
Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children
Author(s)Aaron S. Farberg, MD
Aaron Farberg, MD, discuss how appropriate monitoring, including regular assessments of growth, potential side effects, and laboratory tests to evaluate liver function and hematologic parameters, would be necessary when prescribing a topical JAK inhibitor to a younger child (age 2-11 years).
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- What kind of monitoring, if any, do you believe would be necessary when prescribing a topical JAK inhibitor to a younger child (age 2-11 years)?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5
